SIMCERE PHARMA (02096): SIM0609 (CDH17 Antibody-Drug Conjugate) Receives Clinical Trial Approval from National Medical Products Administration

Stock News

Sep 08

SIMCERE PHARMA (02096) announced that on September 5, 2025, the company's independently developed anti-tumor candidate drug SIM0609, a CDH17-targeted antibody-drug conjugate (ADC), has received clinical trial approval notification from China's National Medical Products Administration to conduct clinical trials for advanced solid tumors.

SIM0609 is a novel antibody-drug conjugate targeting cadherin-17 (CDH17), composed of a humanized monoclonal antibody conjugated with the company's proprietary novel water-soluble cleavable linker and the company's independently developed novel topoisomerase I (TOP-I) inhibitor.

CDH17 is highly expressed in multiple types of cancer, including gastric cancer, colorectal cancer, and pancreatic cancer, demonstrating potential as a therapeutic target for advanced solid tumors, particularly gastrointestinal tumors.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1183330433"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1183330433\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1183330433?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-08 20:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1183330433","market":"nz","top_or_hot":-1,"title":"SIMCERE PHARMA (02096): SIM0609 (CDH17 Antibody-Drug Conjugate) Receives Clinical Trial Approval from National Medical Products Administration","media":"Stock News","content":"<p>SIMCERE PHARMA (02096) announced that on September 5, 2025, the company's independently developed anti-tumor candidate drug SIM0609, a CDH17-targeted antibody-drug conjugate (ADC), has received clinical trial approval notification from China's National Medical Products Administration to conduct clinical trials for advanced solid tumors.</p>\n<p>SIM0609 is a novel antibody-drug conjugate targeting cadherin-17 (CDH17), composed of a humanized monoclonal antibody conjugated with the company's proprietary novel water-soluble cleavable linker and the company's independently developed novel topoisomerase I (TOP-I) inhibitor.</p>\n<p>CDH17 is highly expressed in multiple types of cancer, including gastric cancer, colorectal cancer, and pancreatic cancer, demonstrating potential as a therapeutic target for advanced solid tumors, particularly gastrointestinal tumors.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SIMCERE PHARMA (02096): SIM0609 (CDH17 Antibody-Drug Conjugate) Receives Clinical Trial Approval from National Medical Products Administration</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSIMCERE PHARMA (02096): SIM0609 (CDH17 Antibody-Drug Conjugate) Receives Clinical Trial Approval from National Medical Products Administration\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-08 20:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SIMCERE PHARMA (02096) announced that on September 5, 2025, the company's independently developed anti-tumor candidate drug SIM0609, a CDH17-targeted antibody-drug conjugate (ADC), has received clinical trial approval notification from China's National Medical Products Administration to conduct clinical trials for advanced solid tumors.</p>\n<p>SIM0609 is a novel antibody-drug conjugate targeting cadherin-17 (CDH17), composed of a humanized monoclonal antibody conjugated with the company's proprietary novel water-soluble cleavable linker and the company's independently developed novel topoisomerase I (TOP-I) inhibitor.</p>\n<p>CDH17 is highly expressed in multiple types of cancer, including gastric cancer, colorectal cancer, and pancreatic cancer, demonstrating potential as a therapeutic target for advanced solid tumors, particularly gastrointestinal tumors.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"","article_id":"1183330433","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1183330433","pubTimestamp":1757333778,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"SIMCERE PHARMA (02096) announced that on September 5, 2025, the company's independently developed anti-tumor candidate drug SIM0609, a CDH17-targeted antibody-drug conjugate (ADC), has received...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1583":"高瓴概念","BK1191":"制药","02096":"先声药业"},"translate_title":"先声药业(02096)：SIM0609(CDH17抗体药物偶联物)获国家药品监督管理局临床试验批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02096":1},"content_text":"SIMCERE PHARMA (02096) announced that on September 5, 2025, the company's independently developed anti-tumor candidate drug SIM0609, a CDH17-targeted antibody-drug conjugate (ADC), has received clinical trial approval notification from China's National Medical Products Administration to conduct clinical trials for advanced solid tumors.\nSIM0609 is a novel antibody-drug conjugate targeting cadherin-17 (CDH17), composed of a humanized monoclonal antibody conjugated with the company's proprietary novel water-soluble cleavable linker and the company's independently developed novel topoisomerase I (TOP-I) inhibitor.\nCDH17 is highly expressed in multiple types of cancer, including gastric cancer, colorectal cancer, and pancreatic cancer, demonstrating potential as a therapeutic target for advanced solid tumors, particularly gastrointestinal tumors.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}